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40-word summary: The risk of developing Kaposi sarcoma after starting combination 
antiretroviral therapy is substantial in HIV-infected children of sub-Saharan African origin, 
whether they live in Africa or Europe, but low in children of non-sub-Saharan African origin 
in Europe and in Asia. 
Abstract (250 words, max. 250) 
Background: The burden of Kaposi sarcoma (KS) in HIV-infected children and adolescents on 
combination antiretroviral therapy (cART) has not been estimated and compared globally.  
Methods: We analyzed cohort data from the International Epidemiologic Databases to 
Evaluate AIDS, and the Collaboration of Observational HIV Epidemiological Research in 
Europe. We included HIV-infected children aged <16 years at initiation of cART from 1996 
onwards. We used Cox models to calculate hazard ratios (HR), adjusted for region and origin, 
sex, age at cART initiation, HIV/AIDS stage at cART initiation and cART start year. 
Results: We included a total of 24,991 children from Eastern Africa, Southern Africa, Europe 
and Asia; 26 developed KS after starting cART. Incidence rates per 100,000 person-years 
(pys) were 86 in Eastern Africa (95% confidence interval [CI] 55-133), 11 in Southern Africa 
(95% CI 4-35), and 81 (95% CI 26-252) in children of sub-Saharan African (SSA) origin in 
Europe. The KS incidence rates were 0/100,000 pys in children of non-SSA origin in Europe 
(95% CI 0-50) and in Asia (95% CI 0-27). KS risk was lower in girls than boys (adjusted HR 0.3, 
95% CI 0.1-0.9), and increased with age (10-15 versus 0-4 years; adjusted HR 3.4; 95% CI 1.2-
10.1) and advanced HIV/AIDS stage (CDC stage C versus A/B; adjusted HR 2.4; 95% CI 0.8-7.3) 
at cART initiation.  
Conclusions: HIV-infected children and adolescents from SSA, but not those from other 
regions, have a high risk of developing KS after cART initiation. In these children early cART 
initiation might reduce KS risk. 
  
Introduction 
HIV-infected children and adolescents are at increased risk of developing Kaposi sarcoma 
(KS) [1]. In the era of combination antiretroviral therapy (cART), reported KS incidence rates 
in HIV-infected children vary between 17 and 150 per 100,000 person-years (pys) [2–6]. 
Although these KS incidence rates are generally lower than in the pre-cART era [1–3,7], they 
still exceed the incidence rates of all cancer types combined in children from the general 
population. For example, the overall cancer incidence rate per 100,000 pys is 14 in children 
and adolescents in Europe, 10 in Eastern Africa, and 5 in Southern Africa [8]. In addition, 
mortality from KS in HIV-infected children remains substantial in resource-limited regions 
[9,10]. Median survival was below six months in a recent trial from Malawi [10]. 
Immune deterioration following uncontrolled HIV replication increases the risk of developing 
KS in children co-infected with human herpesvirus 8 (HHV-8). HHV-8 seroprevalence in the 
general population differs across sub-Saharan Africa (SSA), Europe and Asia. However, few 
studies reported HHV-8 seroprevalence data for HIV-infected children. Around 40% of HIV-
infected infants in Zambia and 30% of children in South Africa (mean age: 5.5 years) are 
seropositive for HHV-8 [11,12]. Children born in Western Europe have a lower risk of HHV-8 
co-infection than children born in SSA and other parts of the world [13]. HHV-8 
seroprevalence among HIV-infected children from Asia has not been reported, but studies in 
HIV-infected adults indicate that HHV-8 seroprevalence is lower in this region than in SSA 
[14,15].  
Combination ART suppresses HIV replication, restores immune function and subsequently 
reduces the risk of developing KS [3,5]. However, access to cART differs across regions. In 
2013, pediatric cART coverage reached 95% in Europe, but only about 25% in Africa and 
Southeast Asia [16]. The majority of HIV-infected children from low- or middle-income 
countries initiate cART when severely immunosuppressed [17]. African-born children who 
have migrated to Europe also start cART at older ages and in more immunosuppressed 
stages than children born in Europe [18,19]. 
Despite these regional differences in HHV-8 exposure and access to healthcare, KS risk 
among HIV-infected children and adolescents has not been directly compared across 
regions. We collaborated with the International Epidemiologic Databases to Evaluate AIDS 
(IeDEA) and the Collaboration of Observational HIV Epidemiological Research in Europe 
(COHERE) in EuroCoord to compare KS incidence rates and associated risk factors in HIV-
infected children and adolescents who initiated cART in Eastern Africa, Southern Africa, 
Europe, and Asia. 
Methods 
Databases 
We analyzed data from observational HIV cohorts which systematically collect data on KS in 
children and adolescents and participate in the IeDEA Southern Africa (IeDEA-SA) [20]; the 
IeDEA Asia-Pacific’s TREAT Asia Pediatric HIV Observational Database (TApHOD) [21]; or the 
COHERE in EuroCoord [22]. IeDEA-SA includes seven cART programs in South Africa, Zambia 
and Zimbabwe that collect KS data in children and adolescents systematically [20] or 
obtained these data through a record linkage with pediatric oncology departments [5]. 
TApHOD combines data from 18 pediatric clinics in Cambodia, India, Indonesia, Malaysia, 
Thailand, and Vietnam. Data on HIV-infected children and adolescents from 11 cohorts in 
nine European countries (Austria, Denmark, France, Germany, Greece, Netherlands, Spain, 
the UK and Ireland) were included through the COHERE in EuroCoord 2014 dataset. All 
included cohorts collect demographic, clinical, treatment and outcome data on children and 
adolescents with HIV. Ethical approval for each cohort was obtained from local ethics 
committees or institutional review boards.   
Inclusion criteria and definitions 
We included all HIV-infected children and adolescents <16 years of age at cART initiation in 
or after 1996. We excluded children who initiated cART before enrollment into a cohort and 
children without follow-up on cART including those who developed KS before initiating cART. 
Cohorts with ≤10 eligible children were excluded. KS cases were either histologically 
confirmed or clinically diagnosed only. Because risk of HHV-8 infection varies by place of 
residence and place of birth, we stratified the data by geographic region of the cohort (Asia, 
Eastern Africa, Southern Africa) and among those in Europe, by the child’s place of birth 
(European children of SSA origin and European children of non-SSA origin). Geographic 
regions were defined according to the United Nations classification and do not necessarily 
correspond to consortia regions [23]. We used WHO 2007 growth reference standards to 
calculate sex-standardized weight-for-age z-scores (WAZ) at cART initiation for children <10 
years at time of measurement [24,25]. A WAZ of below -3 was considered as severely 
underweight. Children aged ≥10 years were excluded from WAZ analyses, because WAZ are 
not recommended as a growth measure in older children and adolescents [25]. CD4 cell 
count at cART initiation was defined as the measurement closest to initiation within 180 
days before to seven days after cART initiation. Children <5 years were excluded from CD4 
cell count analyses because CD4% is recommended for this age group [26]. 
Immunodeficiency at cART initiation was categorized into no, mild, advanced and severe 
according to WHO 2007 surveillance criteria [26]. Clinical HIV/AIDS stage at cART initiation 
was defined according to the US Centers for Disease Control and Prevention (CDC) criteria 
[27]. We defined cART as a regimen of at least three antiretroviral (ARV) drugs from any 
class, including protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), 
and non-nucleoside reverse transcriptase inhibitors (NNRTIs). We considered KS diagnosed 
before or at cART initiation to be prevalent KS, and KS diagnosed after cART initiation to be 
incident KS.   
Statistical methods 
We calculated KS incidence rates by dividing the number of children who developed KS by 
person-years at risk. Time at risk was measured from cART initiation to KS diagnosis, last 
follow-up visit, death, or database closure, whichever occurred first. Observation time was 
not right censored at a specific age. We calculated KS incidence rates for the overall 
observation period, and by time periods after cART initiation, i.e., 0-3 months, 4-6 months, 
7-12 months, 13-36 months, and >36 months. We ignored interruptions or treatment 
changes to cART. Crude and adjusted Cox proportional hazards models were used to 
describe risk factors for incident KS. We assessed the following risk factors: cohort region 
and child’s origin (Eastern Africa, Southern Africa, Europe with SSA origin, Europe non-SSA 
origin, Asia); sex; age at cART initiation; first-line cART regimen (NNRTI-based, PI-based, 
other regimen); calendar period of cART initiation (1996-2003, 2004-2007, 2008-2014); CD4 
cell count at cART initiation (<200 cells/µl, ≥200 cells/µl); CD4% at cART initiation (<10%, 10-
19%, ≥20%) and CDC stage at cART initiation (A/B, C). The multivariable Cox model included 
region and origin, sex, age, CDC stage and calendar period of cART initiation. In sensitivity 
analyses, we censored follow-up time at one year after cART initiation, and we restricted the 
analyses to children at increased risk of HHV-8 infection, i.e. those in Eastern and Southern 
Africa and children of SSA origin in Europe [11-13]. Results are presented as medians with 
interquartile ranges (IQR), percentages, incidence rates per 100,000 pys with 95% 
confidence intervals (CIs), or hazard ratios (HRs) with 95% CIs. All analyses were done in 
Stata 13.1 (Stata Corporation, College Station, Texas, USA). 
Results 
Study population 
The database included 35,133 HIV-infected children and adolescents. We excluded 3,321 
because they did not initiate cART or had a missing cART start date. Another 6,821 children 
were excluded for reasons detailed in Figure 1. We excluded 53 children with prevalent KS; 
26 from Eastern Africa, 22 from Southern Africa, three of SSA origin in Europe, and two from 
Asia. Children with prevalent KS were more often female than those with incident KS (43% 
versus 31%), but median age at KS diagnosis was similar (both 9.6 years). We included data 
on 24,991 children and adolescents from 16 countries in Eastern Africa (Zimbabwe, Zambia); 
Southern Africa (South Africa); Europe (Denmark, France, Germany, Ireland, Netherlands, 
Spain, and the UK); and Asia (Cambodia, India, Indonesia, Malaysia, Thailand, Vietnam). Most 
children included in Eastern Africa were located in Zambia (91%, n=10,173); in Europe the 
majority came from the UK and Ireland (63%, n=1,005) and in Asia, 43% (n=1,325) were 
located in Thailand. In Europe, 41% (n=658) of the included children originated from SSA; 
67% (n=444) of these were born in Eastern Africa. Excluded children were less likely to live in 
Eastern Africa than included children (27% versus 45%), but the sex distribution was the 
same (both 50%).  
Median age at cART initiation was 5.0 years (IQR 1.8-9.1) and varied across regions (Table 1). 
It was lowest in Southern Africa and in European children of non-SSA origin, and highest in 
European children of SSA origin. More than one third of children in Southern Africa and 
Europe were treated with PI-based first-line regimens, but ARVs from this class were 
prescribed rarely in Asia (5%) and Eastern Africa (<1%). In Europe, most children of non-SSA 
origin (52%) initiated cART between 1996 and 2003, whereas only 34% of children of SSA 
origin living in Europe and even fewer children from Asia, Eastern and Southern Africa 
initiated cART before 2004. About 20% of children aged <10 years in Eastern Africa, Southern 
Africa and Asia were severely underweight at cART initiation, whereas <5% of children below 
the age of 10 were severely underweight in Europe. Children in Asia tended to start cART 
with lower CD4 cell counts and lower CD4% than those from other regions. Overall, the 
majority of children (63%) started cART with advanced or severe immunodeficiency, but for 
21% (n=5,314) we could not determine the degree of immunosuppression at cART initiation. 
Children with missing CD4 data were younger than those for whom data were available 
(median age: 3.5 years versus 5.5 years), but the proportion with advanced CDC stage C was 
similar (9% versus 10%). The median follow-up time after cART initiation was 2.3 years (IQR 
0.8-4.5 years), and varied across regions; it was longest in European children of non-SSA 
origin (8.0 years) and shortest in Eastern Africa (1.6 years). At the end of follow-up, median 
age ranged between 7.0 years in Southern Africa and 15.1 years in children of SSA origin in 
Europe.  
KS incidence rates and risk factors 
Among 24,991 children and adolescents, 26 developed incident KS during 74,456 pys at risk, 
for an overall KS incidence rate of 35/100,000 pys (95% CI 24-51), see Table 2. Of the 26 
incident KS cases, 20 were observed in Eastern Africa, three in Southern Africa, and three in 
Europe. Median age at KS diagnosis was 9.6 years (IQR 6.4-15.2). All KS cases in Europe 
occurred in children of SSA origin. The KS incidence rate was higher in Eastern Africa 
(86/100,000 pys, 95% CI 55-133) than in Southern Africa (11/100,000 pys, 95% CI 4-35). In 
Europe, the KS incidence rate was 81/100,000 pys (95% CI 26-252) in children of SSA origin, 
but 0/100,000 pys (95% CI 0-50) in those of non-SSA origin. During 13,684 pys in children 
from Asia no incident KS case was recorded (KS incidence rate 0/100,000 pys, 95% CI 0-27). 
The overall KS incidence rate was highest in the first three months after cART initiation 
(207/100,000 pys, 95% CI 117-364), and declined steeply thereafter (Figure 2). Of the 26 
incident KS cases, 12 (46%) were diagnosed within the first three months after cART 
initiation. These early KS cases had initiated cART with lower median CD4 cell counts than 
children diagnosed with KS more than three months after cART initiation (90 cells/µl versus 
310 cells/µl).  None of the children who developed KS were diagnosed with Non-Hodgkin’s 
Lymphoma before or after KS diagnosis.  
In univariable analysis, KS risk was higher in European children of SSA origin compared to 
those in Eastern Africa (crude HR 1.8, 95% CI 0.5-6.1), see Table 2. However, the risk became 
similar (adjusted HR 1.0, 95% CI 0.2-6.4) after adjusting for sex, calendar period of cART 
initiation, age, and CDC stage at cART initiation. KS risk was lower in Southern than in 
Eastern Africa (adjusted HR 0.1, 95% CI 0.0-0.6), and increased with age at cART initiation 
(10-15 years versus 0-4 years, adjusted HR 3.4, 95% CI 1.2-10.1) and advanced CDC stage at 
cART initiation (C versus A/B, adjusted HR 2.4, 95% CI 0.8-7.3). KS risk was lower in girls than 
boys (adjusted HR 0.3, 95% CI 0.1-0.9). In multivariable analysis, especially after adjustment 
for region and origin, KS risk seemed to decrease in more recent calendar periods, but CIs 
overlapped widely. When we restricted the analysis to children at increased risk of HHV-8 
co-infection, i.e. those in Eastern and Southern Africa and children of SSA origin in Europe, 
HRs for developing KS remained similar to those estimated in the main analysis (data not 
shown). When we censored follow-up time at one year after cART initiation, KS incidence 
rates per 100,000 pys were 162 in Eastern Africa, 39 in Southern Africa, 320 in children of 
SSA origin in Europe, and 0 in children of non-SSA origin in Europe and in Asia 
(Supplementary Table S1). However, crude and adjusted HRs for developing KS did not 
change much compared to the main analysis (Supplementary Table S1).   
Discussion 
HIV-infected children and adolescents from Eastern and Southern Africa and those of SSA 
origin living in Europe were at highest risk of developing KS after cART initiation. The risk of 
developing KS decreased with time after cART initiation. KS risk was lower in girls than boys, 
and increased with age and advanced HIV/AIDS stage at cART initiation. We did not detect 
any incident KS cases in children from Asia and in European children of non-SSA origin.  
We are the first to directly compare KS incidence rates across regions and to specifically 
examine risk factors for developing KS in HIV-infected children on cART. Previous papers 
looked into overall cancers in HIV-infected children, and did not have sufficient cases for a 
KS-specific analysis [2,3]. Some of the children from Eastern and Southern Africa were 
included in previous studies though [5,6]. Several limitations need to be addressed. Many 
HIV treatment programs in Eastern and Southern Africa only start following children after 
cART initiation. Therefore, we restricted this comparative analysis to children who initiated 
cART. The children in this analysis might not be representative of all HIV-infected children in 
the included geographic regions. For example, all Southern African cART programs were 
located in urban areas of South Africa, and the majority of children from Eastern Africa lived 
in Zambia. KS diagnoses in Eastern Africa were often based on clinical assessment without 
histological confirmation, which might have led to an over- or under-estimation of KS 
incidence rates in children from this region. For Southern Africa, KS ascertainment was 
improved through a record linkage with pediatric oncology departments [5]. HIV RNA data 
and CD4 measurements were missing for 65% and 21% of included children, respectively. 
This limited our ability to explore the impact of these biological markers on KS risk. Similarly, 
CDC stage data were missing for 8% of included children and 19% of KS cases which reduced 
the precision of the CDC stage effect estimate. However, the effect size was still 
considerable. Data on HHV-8 infection status were not available. 
In our analyses, all KS cases in Europe were diagnosed in children born in SSA. This has not 
been described before, however, in Europe KS risk is higher in HIV-infected adults from SSA 
than in others [28,29]. Our finding of zero incident KS cases in Asia confirms a study from 
Thailand, which even in the pre-cART era found no incident KS case in 8,034 HIV-infected 
children [30]. In contrast, a small record linkage study from Taiwan reported a KS incidence 
rate of 150/100,000 pys in 230 HIV-infected children [4]. We found that the risk of 
developing incident KS was lower in Southern Africa compared to Eastern Africa. This might 
be partly explained by lower HHV-8 prevalence in Southern Africa than Eastern Africa 
[11,12]. However, we cannot exclude that underreporting of incident KS and limited 
generalizability of our results contributed to this finding. The number of prevalent KS cases 
in Southern Africa was substantial and shows that many children in Southern Africa 
developed KS before initiating cART [31]. In our study, boys had a higher risk of developing 
KS than girls, which has not been shown consistently in previous studies [6,9,32,33]. The 
overall KS incidence rate was highest soon after cART initiation, and declined with time since 
cART initiation. This has not yet been described in children but is consistent with findings 
from previous studies in adults [6,28,34]. The high KS incidence rate soon after cART 
initiation could be a result of unmasking immune reconstitution inflammatory syndrome KS 
[35,36], reflect a slow increase in HHV-8-specific immune response over several months on 
cART [37], or represent the misclassification of prevalent KS cases as incident KS cases. Our 
KS incidence rate estimates are in line with results from previous studies done in the cART 
era (Supplementary Table S2) [2,3,5,6]. However, KS incidence rates from different studies 
should be compared cautiously because of different study designs and settings.  
Our study has shown that KS risk was considerable in HIV-infected children and adolescents 
who were born or lived in SSA. This risk might be driven by high HHV-8 prevalence in these 
children [11–14], and barriers in access to health care [17–19]. We identified older age and 
advanced HIV/AIDS stage at cART initiation as risk factors for incident KS. The later children 
start cART, the longer their HIV infection goes untreated, increasing the risk of 
immunosuppression and subsequent KS. The risk for HHV-8 infection also increases with age 
[38,39]. However, without patient-level data for HHV-8 serostatus it was not possible to 
assess whether this contributed to the higher KS risk in older children. Programs for early 
testing and linkage to care for HIV-infected children still need improvement, especially in SSA 
and in children from SSA now living in Europe [16,19]. WHO guidelines released in 
September 2015 recommend immediate cART initiation in all HIV-infected children 
regardless of immunodeficiency degree [40]. Timely implementation of this 
recommendation may reduce KS burden in at-risk children.   
KS risk is substantial in HIV-infected children and adolescents of SSA origin, whether they live 
in SSA or Europe. Early cART initiation might reduce KS risk in these children. 
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Tables and Figures 
Table 1: Characteristics of included children and adolescents. 
 Eastern Africa Southern 
Africa 
Europe,  
SSA origin 
Europe,  
Non-SSA origin 
Asia 
 N (%) N (%) N (%) N (%) N (%) 
All children 11,163 (100%) 9,174 (100%) 658 (100%) 934 (100%) 3,062 (100%) 
Median follow-up 
time (IQR) [years] 1.6 (0.5-3.4) 2.4 (0.9-4.6) 5.2 (2.6-8.4) 8.0 (4.1-11.7) 4.4 (2.1-6.5) 
Sex      
   Boys 5,547 (50%) 4,582 (50%) 335 (51%) 454 (49%) 1,569 (51%) 
   Girls  5,616 (50%) 4,592 (50%) 323 (49%) 480 (51%) 1,493 (49%) 
Median age at cART 
initiation (IQR) [years] 
6.1  
(2.3-10.3) 
3.4 
 (1.0-7.3) 
8.7  
(5.0-12.1) 
3.3  
(0.6-8.8) 
5. 8  
(3.0-8.8) 
Age at cART initiation 
[years]      
   0-4 4,834 (43%) 5,551 (61%) 163 (25%) 545 (58%) 1,316 (43%) 
   5-9 3,344 (30%) 2,539 (28%) 219 (33%) 199 (21%) 1,205 (39%) 
   10-15 2,985 (27%) 1,084 (12%) 276 (42%) 190 (20%) 541 (18%) 
Median weight for 
age z-score at cART 
initiation (IQR)ⱡ 
-2.0  
(-3.0 to -1.0) 
-1.7  
(-2.7 to -0.7) 
-0.4  
(-1.2 to 0.4) 
-0.4  
(-1.5 to 0.5) 
-2.2  
(-3.2 to -1.2) 
Weight for age z-score 
at cART initiation ⱡ      
   < -3 1,858 (23%) 1,343 (17%) 7 (2%) 27 (4%) 564 (22%) 
   -3 to <-2 1,733 (21%) 1,408 (17%) 22 (6%) 36 (5%) 513 (20%) 
   -2 to <-1 1,929 (24%) 1,795 (22%) 50 (13%) 88 (12%) 490 (19%) 
   ≥ -1 1,774 (22%) 2,088 (26%) 193 (51%) 265 (36%) 419 (17%) 
   Missing 884 (11%) 1,456 (18%) 110 (29%) 328 (44%) 535 (21%) 
First line cART 
regimen      
   NNRTI-based 11,056 (99%) 4,980 (54%) 432 (66%) 434 (46%) 2,859 (93%) 
   PI-based 13 (<1%) 4,174 (46%) 205 (31%) 449 (48%) 157 (5%) 
   Other cART 94 (1%) 20 (<1%) 21 (3%) 51 (5%) 46 (2%) 
Year of cART initiation      
   1996-2003 3 (<1%) 236 (3%) 221 (34%) 484 (52%) 461 (15%) 
   2004-2007 4,958 (44%) 4,496 (49%) 215 (33%) 258 (28%) 1,433 (47%) 
   2008-2014 6,202 (56%) 4,442 (48%) 222 (34%) 192 (21%) 1,168 (38%) 
CDC stage at cART 
initiation 
     
   A/B 9,127 (82%) 8,029 (88%) 528 (80%) 701 (75%) 2,234 (73%) 
cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR, 
interquartile range; KS, Kaposi sarcoma; NNRTI, non-nucleoside reverse-transcriptase inhibitors; PI, 
protease-inhibitors; SSA, sub-Saharan African.  
ⱡ Weight for age z-scores only calculated for children <10 years at time of measurement. 
* WHO 2007 surveillance definition of immunodeficiency [26] 
**Children younger than 5 years were excluded from the analysis of CD4 cell counts. 
  
   C 925 (8%) 907 (10%) 65 (10%) 157 (17%) 370 (12%) 
   Missing 1,111 (10%) 238 (3%) 65 (10%) 76 (8%) 458 (15%) 
Immunodeficiency at 
cART initiation*      
   None/mild 1,754 (16%) 1,470 (16%) 156 (24%) 279 (30%) 331 (11%) 
   Advanced/severe 6,871 (62%) 5,672 (62%) 446 (68%) 473 (51%) 2,225 (73%) 
   Missing 2,538 (23%) 2,032 (22%) 56 (9%) 182 (19%) 506 (17%) 
Median CD4 cell count 
at cART initiation 
(IQR) [cells/µl]** 
241  
(120-403) 
265  
(108-466) 
259  
(135-406) 
290  
(140-469) 
118  
(26-300) 
CD4 cell count at cART 
initiation [cells/µl]** 
     
   <200  2,272 (36%) 1,103 (30%) 172 (35%) 105 (27%) 940 (54%) 
   ≥200 3,175 (50%) 1,734 (48%) 290 (59%) 214 (55%) 567 (32%) 
   Missing 882 (14%) 786 (22%) 33 (7%) 70 (18%) 239 (14%) 
Median CD4% at cART 
initiation (IQR)  
14  
(9-19) 
14  
(8-21) 
14  
(8-20) 
17  
(11-28) 
9  
(3-16) 
CD4% at cART 
initiation 
     
   <10% 2,139 (19%) 2,194 (24%) 168 (26%) 150 (16%) 1,353 (44%) 
   10-19% 3,206 (29%) 2,882 (31%) 260 (40%) 240 (26%) 807 (26%) 
   ≥20% 1,617 (14%) 1,914 (21%) 148 (22%) 316 (34%) 373 (12%) 
   Missing 4,201 (38%) 2,184 (24%) 82 (12%) 228 (24%) 529 (17%) 
Table 2:  KS incidence rates per 100,000 person-years and HRs for developing KS in children and 
adolescents who initiated cART. 
 Patients  
(N) 
Person- 
years  
Cases 
 (N) 
Incidence rate  
(95% CI) 
Crude HR 
(95% CI) 
Adjusted HR 
(95% CI)ᶧ 
Overall 24,991 74,456 26 34.9 (23.8-51.3) - - 
Region and origin       
 Eastern Africa 11,163 23,313 20 85.8 (55.3-133.0) 1.0 1.0 
 Southern Africa 9,174 26,337 3 11.4 (3.7-35.3) 0.2 (0.0-0.5) 0.1 (0.0-0.6) 
 Europe, SSA origin 658 3,694 3 81.2 (26.2-251.8) 1.8 (0.5-6.1) 1.0 (0.2-6.4) 
 Europe, non-SSA 
origin  934 7,428 0 0 (0-49.8) - - 
 Asia 3,062 13,684 0 0 (0-27.0) - - 
Sex       
 Boys 12,487 37,448 18 48.1 (30.3-76.3) 1.0 1.0 
 Girls  12,504 37,009 8 21.6 (10.8-43.2) 0.4 (0.2-1.0) 0.3 (0.1-0.9) 
Age at cART 
initiation [years] 
      
 0-4 12,409 34,923 7 20.0 (9.6-42.0) 1.0 1.0 
 5-9 7,506 25,431 7 27.5 (13.1-57.7) 1.5 (0.5-4.2) 1.2 (0.4-4.3) 
 10-15 5,076 14,102 12 85.1 (48.3-149.8) 3.9 (1.5-10.0) 3.4 (1.2-10.1) 
Weight for age    
z-score at cART 
initiation ⱡ 
      
 < -3 3,799 9,709 0 0 (0-38.1) - - 
 -3 to <-2 3,712 10,408 2 19.2 (4.8-76.8) 1.4 (0.2-9.6) - 
 -2 to <-1 4,352 12,870 7 54.4 (25.9-114.1) 3.9 (0.8-19.0) - 
 ≥ -1 4,739 15,817 2 12.6 (3.2-50.6) 1.0 - 
 Missing 3,313 11,550 3 - - - 
First line cART 
regimen 
      
 NNRTI-based 19,761 57,502 25 43.5 (29.4-64.3) 1.0 - 
 PI-based 4,998 15,945 1 6.3 (0.9-44.5) 0.2 (0.0-1.2) - 
 Other cART 232 1,009 0 - - - 
Year of cART 
initiation 
      
 1996-2003 1,405 12,252 2 16.3 (4.1-65.3) 1.0 1.0 
 2004-2007 11,360 44,121 18 40.8 (25.7-64.8) 1.3 (0.3-5.5) 0.4 (0.0-3.6) 
 2008-2014 12,226 18,084 6 33.2 (14.9-73.9) 0.5 (0.1-2.8) 0.2 (0.0-2.1) 
CDC stage at cART 
initiation 
      
 A/B 20,619 60,261 17 28.2 (17.5-45.4) 1.0 1.0 
cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; CI, 
confidence interval; HR, hazard ratio; NNRTI, non-nucleoside reverse-transcriptase inhibitors; PI, 
protease-inhibitors; SSA, sub-Saharan African.  
 
ⱡ Weight for age z-scores only calculated for children younger than 10 years at time of measurement. 
* Children younger than 5 years were excluded from the analysis of CD4 cell counts. 
ᶧ Adjusted for region and origin, gender, age, year of ART initiation, and CDC stage at cART initiation. 
Number of children and adolescents included in multivariable model: N = 23,043 
  
 C 2,424 7,027 4 56.9 (21.4-151.7) 2.2 (0.7-6.6) 2.4 (0.8-7.3) 
 Missing 1,948 7,168 5 - - - 
CD4 cell count at 
cART initiation 
[cells/µl]* 
      
 <200  4,592 15,331 8 52.2 (26.1-104.3) 1.0 - 
 ≥ 200 5,980 18,265 5 27.4 (11.4-65.8) 0.5 (0.2-1.5) - 
 Missing 2,010 5,937 6 - - - 
CD4% at cART 
initiation 
      
 <10% 6,004 20,563 7 34.0 (16.2-71.4) 1.0 - 
 10-19% 7,395 22,032 3 13.6 (4.4-42.2) 0.4 (0.1-1.4) - 
 ≥20% 4,368 12,003 2 16.7 (4.2-66.6) 0.4 (0.1-2.1) - 
 Missing 7,224 19,858 14 - - - 
Figure 1. Identification of study population for analysis. The flow diagram shows the number of 
included and excluded children and adolescents. cART, combination antiretroviral therapy; KS, Kaposi 
sarcoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exclusions 
24,991 children from 15 cohorts 
included in incidence analysis 
24,965 without KS, 26 with incident KS 
Cohorts with ≤10 eligible children 
4 cohorts with 11 children in total 
35,133 children and adolescents  
in 19 cohorts 
 
27,100 
2,733 children with missing or ill-defined cancer data 
114 children with missing data on sex, start or end of 
observation and children from Europe with missing 
origin information 
 
26,443 
 
3,321 children not on cART or with missing cART 
start date 
32,400 
657 children with start of observation before cancer 
collection period or cART start after last observation 
 
29,079 
 
1,979 children starting cART before 1996 or before 
start of observation period  
26,329 
 
1,327 children without follow-up time on cART 
1,274 without KS, 53 with prevalent KS 
25,002 
 
Figure 2: KS incidence rates in HIV-infected children and adolescents by time after cART initiation. 
 
 
cART, combination antiretroviral therapy; KS, Kaposi sarcoma; pys, person-years. 
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Table S1:  Sensitivity analyses with follow-up time restricted to 1 year after cART initiation: KS 
incidence rates per 100,000 person-years and HRs for developing KS in children who initiated cART. 
 Patients  
(N) 
Person- 
years  
Cases 
 (N) 
Incidence rate  
(95% CI) 
Crude HR 
(95% CI) 
Adjusted HR 
(95% CI)ᶧ 
Overall 24,991 20,648 19 92 (59-144) - - 
Region and origin       
 Eastern Africa 11,163 8,665 14 162 (96-273) 1.0 1.0 
 Southern Africa 9,174 7,648 3 39 (13-122) 0.2 (0.1-0.9) 0.1 (0.0-0.8) 
 Europe, SSA origin 658 625 2 320 (80-1280) 2.1 (0.5-9.4) 0.4 (0.0-7.4) 
 Europe, non-SSA 
origin  934 908 0 0 (0-407) - - 
 Asia 3,062 2,803 0 0 (0-132) - - 
Sex       
 Boys 12,487 10,324 14 136 (80-229) 1.0 1.0 
 Girls  12,504 10,324 5 48 (20-116) 0.4 (0.1-1.0) 0.3 (0.1-0.9) 
Age at cART 
initiation [years] 
      
 0-4 12,409 9,761 5 51 (21-123) 1.0 1.0 
 5-9 7,506 6,562 5 76 (32-183) 1.5 (0.4-5.3) 1.1 (0.2-4.8) 
 10-15 5,076 4,325 9 208 (108-400) 4.2 (1.4-12.4) 3.7 (1.1-12.6) 
Weight for age    
z-score at cART 
initiation ⱡ 
      
 < -3 3,799 2,926 0 0 (0-126) - - 
 -3 to <-2 3,712 3,045 2 66 (16-263) 2.7 (0.2-29.3) - 
 -2 to <-1 4,352 3,636 5 138 (57-330) 5.6 (0.7-47.7) - 
 ≥ -1 4,739 4,108 1 24 (3-173) 1.0 - 
 Missing 3,313 2,608 2 - - - 
First line cART 
regimen 
      
 NNRTI-based 19,761 16,452 18 109 (69-174) 1.0 - 
 PI-based 4,998 4,014 1 25 (4-177) 0.2 (0.0-1.7) - 
 Other ART 232 181 0 - - - 
Year of cART 
initiation 
      
 1996-2003 1,405 1,360 2 147 (37-588) 1.0 1.0 
 2004-2007 11,360 10,239 11 107 (59-194) 0.7 (0.2-3.2) 0.1 (0.0-1.8) 
 2008-2014 12,226 9,049 6 66 (30-148) 0.4 (0.1-2.0) 0.1 (0.0-1.4) 
CDC stage at cART 
initiation 
      
 A/B 20,619 17,128 11 64 (36-116) 1.0 1.0 
 C 2,424 1,805 4 222 (83-590) 3.4 (1.1-10.5) 3.6 (1.1-11.6) 
 Missing 1,948 1,715 4 - - - 
cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; CI, 
confidence interval; HR, hazard ratio; KS, Kaposi sarcoma; NNRTI, non-nucleoside reverse-
transcriptase inhibitors; PI, protease-inhibitors; SSA, sub-Saharan African.  
 
ⱡ Weight for age z-scores only calculated for children younger than 10 years at time of measurement. 
* WHO 2007 surveillance definition of immunodeficiency [26] 
** Children younger than 5 years were excluded from the analysis of CD4 cell counts. 
ᶧ Adjusted for region and origin, gender, age, year of ART initiation, and CDC stage at cART initiation. 
Number of children and adolescents included in multivariable model: N = 23,043 
 
 
CD4 cell count at 
cART initiation 
[cells/µl]** 
      
 <200  4,592 3,925 7 178 (85-374) 1.0 - 
 ≥ 200 5,980 5,232 3 57 (18-178) 0.3 (0.1-1.2) - 
 Missing 2,010 1,729 4 - - - 
CD4% at cART 
initiation 
      
 <10% 6,004 5,081 6 118 (53-263) 1.0 - 
 10-19% 7,395 6,145 2 33 (8-130) 0.3 (0.1-1.4) - 
 ≥20% 4,368 3,472 1 29 (4-204) 0.2 (0.0-2.0) - 
 Missing 7,224 5,950 10 - - - 
 33 
 
Table S2: Literature review of studies reporting KS incidence rates in HIV-infected children and adolescents in the cART era. 
Author, year Cohort/Study Country Calendar years 
Children 
(N) 
Incident KS cases 
(N) 
KS incidence rate per  
100,000 person-years 
Chiappini et al. 2007 2 Italian Register for HIV Infection in Children Italy 2000-2004 787 1 38 
Simard et al. 2012 3 HIV/AIDS Cancer Match Study* USA 1996-2007 1,370 3 17 
Chen et al. 2015 4 NHIRD Taiwan 1998-2009 230 2 150 
Bohlius et al. 2016 5 IeDEA-SA South Africa 2004-2011 11,707 10† 34 
Rohner et al. 2014 6 IeDEA-SA Botswana, South Africa, Zambia, Zimbabwe 2004-2011 13,249 16† 59** 
Current analysis 
IeDEA-SA 
COHERE in EuroCoord 
TApHOD 
South Africa, Zambia, Zimbabwe 
Denmark, France, Germany, 
Netherlands, Spain, UK, Ireland 
Cambodia, India, Indonesia, 
Malaysia, Thailand, Vietnam 
1996-2014 25,033 26† 35** 
* included children and adolescents diagnosed with AIDS only; † Three KS cases from Bohlius et al. 2016 5 and 14 KS cases from Rohner et al. 2014 6 were 
included in the current analysis; ** included children and adolescents who initiated cART only 
COHERE, Collaboration of Observational HIV Epidemiological Research in Europe; IeDEA-SA, International Epidemiologic Databases to Evaluate AIDS Southern 
Africa; NHIRD, National Health Insurance Research Database; TApHOD, TREAT Asia Pediatric HIV Observational Database; cART, combination antiretroviral 
therapy; KS, Kaposi sarcoma; N, number.  
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